Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Chronic hepatitis C (HCV) infected patients with coexisting mental health and/or substance abuse issues face significant barriers to treatment and are often deferred. This paper sought to highlight critical pre-treatment strategies and provide tangible resources for HCV clinicians to facilitate preparation and successful treatment of these patients.
Guided by the clinical experience of our liver center, a large, tertiary academic medical center, and informed by the extant literature, we summarize pre-treatment strategies and specific resources and recommendations for HCV providers.
Four key pre-treatment strategies include: 1) screening for mental health/substance abuse issues using brief, reliable and validated instruments; 2) locating and establishing collaborative care with mental health and substance abuse specialists; 3) using a motivational interviewing communication style; and 4) addressing adherence-related issues.
HCV clinicians are in a unique position to prepare patients with coexisting mental health and/or substance abuse issues for antiviral therapy.
- U.S. Food and Drug Administration. FDA approves Victrelis for Hepatitis C [FDA News Release web site]. May 13, 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm. Accessed 7 June 2011.
- U.S. Food and Drug Administration. FDA approves Incivek for hepatitis C [FDA News Release web site]. May 23, 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm. Accessed 20 March 2012.
- Volk, ML (2010) Antiviral therapy for hepatitis C: why are so few patients being treated?. J Antimicrob Chemother 65: pp. 1327-1329 CrossRef
- Volk, ML, Tocco, R, Saini, S (2009) Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50: pp. 1750-1755 CrossRef
- Davis, GL, Alter, MJ, El-Serag, H (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: pp. 513-521 CrossRef
- Kramer, JR, Kanwal, F, Richardson, P (2011) Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 106: pp. 483-491 CrossRef
- Kanwal, F, Hoang, T, Spiegel, BM (2007) Predictors of treatment in patients with chronic hepatitis C infection—role of patient versus nonpatient factors. Hepatology 46: pp. 1741-1749 CrossRef
- Stepanova, M, Kanwal, F, El-Serag, HB (2011) Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 53: pp. 737-745 CrossRef
- Evon, DM, Verma, A, Dougherty, KA (2007) High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 52: pp. 3251-3258 CrossRef
- Muir, AJ, Provenzale, D (2002) A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 34: pp. 268-271 CrossRef
- Falck-Ytter, Y, Kale, H, Mullen, KD (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136: pp. 288-292
- Butt, AA, Wagener, M, Shakil, AO (2005) Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 12: pp. 81-85 CrossRef
- Schaefer, M, Schmidt, F, Folwaczny, C (2003) Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37: pp. 443-451 CrossRef
- Schaefer, M, Heinz, A, Backmund, M (2004) Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction 99: pp. 1167-1175 CrossRef
- Schaefer, M, Schwaiger, M, Garkisch, AS (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42: pp. 793-798 CrossRef
- Schaefer, M, Hinzpeter, A, Mohmand, A (2007) Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46: pp. 991-998 CrossRef
- Grebely, J, Genoway, K, Khara, M (2007) Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 18: pp. 437-443 CrossRef
- Knott, A, Dieperink, E, Willenbring, ML (2006) Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 101: pp. 2254-2262 CrossRef
- Sylvestre, DL, Loftis, JM, Hauser, P (2004) Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 81: pp. 719-734 CrossRef
- Sylvestre, DL (2005) Treating hepatitis C virus infection in active substance users. Clin Infect Dis 40: pp. S321-S324 CrossRef
- Sylvestre, DL, Clements, BJ (2007) Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 19: pp. 741-747 CrossRef
- Matthews, G, Kronborg, IJ, Dore, GJ (2005) Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 40: pp. S325-S329 CrossRef
- Freedman, K, Nathanson, J (2009) Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Rev Anti Infect Ther 7: pp. 363-376 CrossRef
- Zanini, B, Covolo, L, Donato, F (2010) Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther 32: pp. 2139-2159 CrossRef
- Bruggmann, P, Falcato, L, Dober, S (2008) Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 15: pp. 747-752 CrossRef
- Bruggmann, P, Dampz, M, Gerlach, T (2010) Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend 110: pp. 167-171 CrossRef
- Evon DM, Esserman DA, Rao T, et al. Patient missed doses and treatment non-persistence during PEG/Ribavirin therapy for chronic hepatitis C: implications for triple therapy and beyond. Hepatology. 2011;54:869A.
- Leutscher, PD, Lagging, M, Buhl, MR (2010) Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 52: pp. 430-435 CrossRef
- Radloff, LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1: pp. 385-401 CrossRef
- Evon, DM, Ramcharran, D, Belle, SH (2009) Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the VIRAHEP-C study. American Journal of Gastroenterology 104: pp. 2949-2958 CrossRef
- Beck, AT, Steer, RA, Ball, R (1996) Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 67: pp. 588-597 CrossRef
- Kroenke, K, Spitzer, RL, Williams, JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16: pp. 606-613 CrossRef
- Hirschfeld, RM, Williams, JB, Spitzer, RL (2000) Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 157: pp. 1873-1875 CrossRef
- Nassir, GS, Miller, CJ, Berv, DA (2005) Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect Disord 84: pp. 273-277 CrossRef
- Saunders, JB, Aasland, OG, Babor, TF (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88: pp. 791-804 CrossRef
- Yudko, E, Lozhkina, O, Fouts, A (2007) A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat 32: pp. 189-198 CrossRef
- Sylvestre, D (2006) Hepatitis C treatment in drug users: perception versus evidence. Eur J Gastroenterol Hepatol 18: pp. 129-130 CrossRef
- Rollnick, S, Miller, W, Butler, C (2007) Motivational Interviewing in Health Care: Helping Patients Change Behavior. The Guilford Press, New York
- Emmons, KM, Rollnick, S (2001) Motivational interviewing in health care settings. Opportunities and limitations. Am J Prev Med 20: pp. 68-74 CrossRef
- Miller, WR, Rollnick, S (2002) Motivational interviewing: preparing people for change. Guilford Press, New York
- Martins, RK, McNeil, DW (2009) Review of motivational interviewing in promoting health behaviors. Clin Psychol Rev 29: pp. 283-293 CrossRef
- Knight, KM, McGowan, L, Dickens, C (2006) A systematic review of motivational interviewing in physical health care settings. Br J Health Psychol 11: pp. 319-332 CrossRef
- Searight, HR (2007) Efficient counseling techniques for the primary care physician. Prim Care 34: pp. 551-570 CrossRef
- Lev-Ran, S, Nitzan, U (2011) Motivational interviewing in health care. Harefuah 150: pp. 749
- Callahan, EJ, Flynn, NM, Kuenneth, CA (2007) Strategies to reduce HIV risk behavior in HIV primary care clinics: brief provider messages and specialist intervention. AIDS Behav 11: pp. S48-S57 CrossRef
- Rubak, S, Sandbaek, A, Lauritzen, T (2005) Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract 55: pp. 305-312
- Miller WR. Enhancing motivation for change in substance abuse treatment. Treatment improvement protocol (TIP) series 35. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. DHHD Publication No. (SMA) 99-3354. Rockville, MD; 1999.
- Rifai, MA, Moles, JK, Lehman, LP (2006) Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics 47: pp. 112-121 CrossRef
- Dieperink, E, Ho, SB, Heit, S (2010) Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics 51: pp. 149-156
- Berg, CJ, Michelson, SE, Safren, SA (2007) Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin North Am 21: pp. 181-200 CrossRef
- Golin, C, Isasi, F, Bontempi, JB (2002) Secret pills: HIV-positive patients’ experiences taking antiretroviral therapy in North Carolina. AIDS Educ Prev 14: pp. 318-329 CrossRef
- Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;CD000011.
- Hendershot, CS, Stoner, SA, Pantalone, DW (2009) Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr 52: pp. 180-202 CrossRef
- McHutchison, JG, Manns, M, Patel, K (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: pp. 1061-1069 CrossRef
- Martin-Santos, R, Diez-Quevedo, C, Castellvi, P (2008) De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 27: pp. 257-265 CrossRef
- Paterson, DL, Swindells, S, Mohr, J (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: pp. 21-30
- Weiden PJ. The adherence interview: Better information, better alliance. Psychiatric Annals Online, 2011; 41 (online only). Available at: http://www.psychiatricannalsonline.com/view.asp?rID=84071. Accessed 15 June 2011.
- Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. AIDS Care. (Epub ahead of print). doi:10.1080/09540121.2011.630354.
- Zolnierek, KB, Dimatteo, MR (2009) Physician communication and patient adherence to treatment: a meta-analysis. Med Care 47: pp. 826-834 CrossRef
- Martin, LR, Williams, SL, Haskard, KB (2005) The challenge of patient adherence. Ther Clin Risk Manag 1: pp. 189-199
- Tanioka, D, Iwasaki, Y, Araki, Y (2009) Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient’s motivation and physician’s treatment experience. Liver Int 29: pp. 721-729 CrossRef
- Simoni, JM, Amico, KR, Pearson, CR (2008) Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep 10: pp. 515-521 CrossRef
- Golin, CE, Liu, H, Hays, RD (2002) A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 17: pp. 756-765 CrossRef
- Vezali, E, Aghemo, A, Colombo, M (2011) Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther 11: pp. 301-313 CrossRef
- Kanwal, F, Hoang, T, Kramer, JR (2011) Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140: pp. 1182-1188 CrossRef
- Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C
Digestive Diseases and Sciences
Volume 57, Issue 6 , pp 1439-1444
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Substance abuse
- Industry Sectors